血液系统恶性肿瘤中的血管生成

Angiogenesis in hematologic malignancies.

作者信息

Moehler T M, Ho A D, Goldschmidt H, Barlogie B

机构信息

Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

出版信息

Crit Rev Oncol Hematol. 2003 Mar;45(3):227-44. doi: 10.1016/s1040-8428(02)00135-x.

DOI:10.1016/s1040-8428(02)00135-x

PMID:12633837

Abstract

Angiogenesis is defined as the formation of new capillaries from preexisting blood vessels and plays an important role in the progression of solid tumors. Recently a similar relationship has been described in several hematologic malignancies. Expression of the angiogenic peptides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor correlates with clinical characteristics in leukemia and non-Hodgkin's-lymphoma and the serum/plasma concentrations serve as predictors of poor prognosis. Increased bone marrow microvessels in multiple myeloma (MM) are correlated with decreased overall survival. Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in MM, myelodysplastic syndrome and acute myeloid leukemia (AML). Preliminary data indicate activity of VEGF-tyrosine kinase inhibitors in AML. Clinical research is now aimed at testing antiangiogenic treatment strategies in several hematologic neoplasms as well as identifying the best candidate patients for specific approaches.

摘要

血管生成被定义为从已有的血管形成新的毛细血管，并且在实体瘤的进展中起重要作用。最近，在几种血液系统恶性肿瘤中也描述了类似的关系。血管生成肽血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子的表达与白血病和非霍奇金淋巴瘤的临床特征相关，并且血清/血浆浓度可作为预后不良的预测指标。多发性骨髓瘤（MM）中骨髓微血管的增加与总生存期的降低相关。已发现具有抗血管生成作用和直接细胞毒性作用的沙利度胺在MM、骨髓增生异常综合征和急性髓系白血病（AML）中有效。初步数据表明VEGF酪氨酸激酶抑制剂在AML中有活性。临床研究目前旨在测试几种血液系统肿瘤的抗血管生成治疗策略，以及确定特定方法的最佳候选患者。